U.S. License Holder:
Mylan / Biocon
Date of License:
aBLA accepted by FDA March-2020
Last Update:
January-23-2023
FDA-Approved Indications
MYL-1402O (bevacizumab) is not FDA-approved. An aBLA has been accepted by the FDA.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In Canada
Abevmy (Biocon / Viatris) (November-2021)
Biosimilars Approved In The E.U.
Abevmy (Biocon / Viatris) (April-2021)